Monday, April 15
Jos Jonkers (The Netherlands Cancer Institute, Amsterdam, NL)
Chair: Jos Jonkers (The Netherlands Cancer Institute, Amsterdam, NL)
Leveraging preclinical models of breast cancer
Tuesday, April 16
Session 1: Hormones and Breast Cancer
Chair: Cathrin Brisken (Ecole Polytechnique Fédérale, Lausanne, CH)
Myles Brown (Dana-Farber Cancer Institute, Boston, US)
Essential genes and cistromes regulating breast cancer hormone dependence
Luca Magnani (Imperial College, London, UK)
Diving into the dark matter of the breast cancer genome
Joyce M Slingerland (University of Miami Miller School of Medicine, Miami, US)
Estrone cooperates with the NFkB pathway to promote obesity-driven inflammation and postmenopausal ER+ breast cancer progression
Session 2: In vitro and in vivo models of Breast Cancer
Chair: Mohamed Bentires-Alj (University of Basel, Basel, CH)
Senthil Muthuswamy (Beth Israel Deaconess Medical Center, Boston, US)
Cell polarity proteins, patient derived organoids and endocrine resistance
Carol Sartorius (University of Colorado, Aurora, US)
Progestin action in luminal and luminobasal models of breast cancer
Cathrin Brisken (Ecole Polytechnique Fédérale, Lausanne, CH)
Humanizing the mouse mammary gland to study hormone-dependent breast carcinogenesis
Session 3: Signaling pathway crosstalk
Chair: Jean J. Zhao (Dana-Farber Cancer Institute, Boston, US)
René Bernards (Netherlands Cancer Institute, Amsterdam, NL)
Exploiting senescence for cancer therapy
William J. Muller (Rosalind and Morris Goodman Cancer Center, Montreal, CA)
Evaluating the role of Integrin signaling in breast cancer dormancy
Wednesday, April 17
Session 4: Breast cancer genomics and evolution
Chair: William J. Muller (Rosalind and Morris Goodman Cancer Centre, Montreal, CA)
Carlos Caldas (Cancer Research UK Cambridge Institute, Cambridge, UK)
Know thy enemy: Landscapes of lethal breast cancer
Steffi Oesterreich (University of Pittsburgh, Pittsburgh, US)
Estrogen receptor mutations
Mohamed Bentires-Alj (University of Basel, Basel, CH)
Cancer targeted therapy and tumor heterogeneity: Act locally, think globally
Karin E. de Visser (Netherlands Cancer Institute, Amsterdam, NL)
The genetic makeup of primary breast cancer dictates pro-metastatic systemic inflammation
Jean Zhao (Dana-Farber Cancer Institute, Boston, US)
Integrating immunotherapy and targeted therapies in cancer treatment: from mouse models to human therapies
Kornelia Polyak (Dana-Farber Cancer Institute, Boston, US)
Immunotherapies and immunoprevention in breast cancer
Morag Park (Rosalind and Morris Goodman Cancer Center, Montreal, CA)
Functional heterogeneity of the triple-negative breast cancer microenvironment
Session 6: Mammary gland biology and stem cells
Chair: Edith C. Kordon (IFIBYNE-UBA-CONICET, University of Buenos Aires, Buenos Aires, AR)
Alexandra Van Keymeulen (Université Libre de Bruxelles, Bruxelles, BE)
Multipotency and lineage segregation of mammary stem cells
Silvia Fre (Institut Curie, Paris, FR)
New approaches to study mammary cell fate specification during embryonic morphogenesis
Jacco van Rheenen (Netherlands Cancer Institute, Amsterdam, NL)
Dissection of the cellular composition of breast tumors for optimal treatment selection
Proffered abstracts session 1
Chair: Kornelia Polyak (Dana-Farber Cancer Institute, Boston, US)
Walid T. Khaled (University of Cambridge, Cambridge, UK)
Building a Comprehensive Human Breast Cell Atlas and studying early stages of TNBC by using scRNAseq
Kienan I. Savage (Queen’s University Belfast, Belfast, UK)
Topoisomerase II inhibitors enhance STING-dependent cytokine release and immune checkpoint activation
Robert Clarke (University of Manchester, Manchester, UK)
Regulation of breast cancer stem cell activity by the bone metastatic niche
Thursday, April 18
Matthew J. Ellis (Baylor College of Medicine, Houston, US)
Endocrine Therapy Resistance: new insights
Geoffrey Lindeman (Walter and Eliza Hall Institute of Medical Research, Parkville, AU)
Targeting cell survival pathways in breast cancer using BH3 mimetics
Proffered abstracts session 2
Chair: Robert Clarke (University of Manchester, Manchester, UK)
Gastón Soria (Universidad Nacional de Córdoba, Córdoba, AR)
Polo-like Kinase 1 inhibition as a novel therapeutic approach to target BRCA1-deficient cancer cells by synthetic lethality induction
Jennifer K. Richer (University of Colorado, Aurora, US)
Clinical biopsies and preclinical models reveal new therapeutic targets in estrogen receptor mutant metastatic breast cancer
Douglas Perkins (The Institute of Cancer Research, London, UK)
A role for senescent fibroblasts in breast cancer metastasis
Chair: John Hilkens (The Netherlands Cancer Institute, Amsterdam, NL)
Lgr5 Stem Cell-based organoids in human disease